Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms
(including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon …

Acinetobacter baumannii is regarded as a life-threatening pathogen associated with
community-acquired and nosocomial infections, mainly pneumonia. The rise in the number …

Acinetobacter baumannii is recognized as a clinically significant pathogen causing a wide
spectrum of nosocomial infections. Colistin was considered a last-resort antibiotic for the …

The management of carbapenem-resistant infections is often based on polymyxins,
tigecycline, aminoglycosides and their combinations. However, in a recent systematic …

Tigecycline is regarded as a last-resort treatment for multidrug-resistant Acinetobacter
baumannii. However, tigecycline resistance in A. baumannii has increased worldwide. In …

Background: Acinetobacter baumannii is a common cause of multi-drug (MDR)-resistant
infections worldwide. The epidemiological and molecular characteristics of MDR-A …

Background: Colistin is one of the few remaining options for carbapenem-resistant
Acinetobacter baumannii (A. baumannii); however, emergence of resistance from …

Antibiotic resistance occurs when microorganisms resist the drugs used against the infection
caused by them and neutralize their effects over time using various mechanisms. These …

Introduction The development of colistin resistance in Acinetobacter baumannii during
treatment has been identified in certain patients, often leading to prolonged or recurrent …

Purpose Pending approval of new antimicrobials, synergistic combinations are the only
treatment option against pandrug-resistant A. baumannii (PDRAB). Considering the lack of a …